Merck Serono, EMD Serono resume Stimuvax clinical program for NSCLC

[News]

Merck Serono, a division of Merck KGaA, and its U.S. affiliate, EMD Serono, Inc. today announced that they are resuming their Stimuvax® (BLP25 liposome vaccine) clinical program in patients with non-small cell lung cancer (NSCLC) which includes the Phase III studies, STARTa and INSPIREb. The treatment and enrollment in these studies will restart after approval by the local regulatory authorities and ethics committees.

More... (http://www.news-medical.net/news/20100617/Merck-Serono-EMD-Serono-resume-Stimuvax-clinical-program-for-NSCLC.aspx)